Companies › Swedish Orphan Biovitrum
4 active drug programs in 36 registered trials: 19 Phase 2, 9 Phase 1, 5 Phase 3, 3 Phase 4; Hematology, Immunology, Oncology, Cardiovascular; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Efanesoctocog alfa Coagulation factor VIII exogenous protein | F8 | Phase 4 | Haemophilia A (Moderate or Severe); Hemophilia A | Nov 2026 |
| Pegcetacoplan Complement C3 inhibitor | C3 | Phase 4 | C3 Glomerulopathy (C3G) | Dec 2031 |
| Pacritinib Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Activin receptor type-1 inhibitor | JAK2, FLT3, ACVR1, IRAK1 | Phase 3 | Primary Myelofibrosis; VEXAS; Myelofibrosis; Acute Myeloid Leukemia … | Dec 2026 |
| Anakinra Interleukin-1 receptor antagonist | IL1R1 | Phase 3 | Still's Disease, Juvenile Onset; FMF; Kawasaki Disease; Premature Infants … | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05814159 | Anakinra | Phase 3 | Still's Disease, Juvenile Onset | Immunology | Dec 2025 |
| NCT04520269 | Pacritinib | Phase 1 | Breast Cancer | Oncology | Jul 2026 |
| NCT06752850 | Efanesoctocog alfa | Phase 4 | Haemophilia A (Moderate or Severe) | Hematology | Nov 2026 |
| NCT06336733 | Anakinra | Phase 3 | FMF | Other | Dec 2026 |
| NCT07254000 | Anakinra | Phase 2 | Premature Infants | Immunology | Dec 2026 |
| NCT06782373 | Pacritinib | Phase 2 | VEXAS | Hematology | Dec 2026 |
| NCT03587701 | Anakinra | Phase 2 | Autoimmune Inner Ear Disease | Immunology | Dec 2026 |
| NCT03645824 | Pacritinib | Phase 2 | Myelofibrosis | Oncology | Feb 2027 |
| NCT05177822 | Anakinra | Phase 2 | Heart Failure | Cardiovascular | Feb 2027 |
| NCT06716814 | Efanesoctocog alfa | Phase 3 | Haemophilia A (Moderate or Severe) | Hematology | Mar 2027 |
| NCT04656184 | Anakinra | Phase 3 | Kawasaki Disease | Immunology | Mar 2027 |
| NCT06538181 | Pacritinib | Phase 1 | E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic Syndrome | Immunology | Mar 2027 |
| NCT04926467 | Anakinra | Phase 2 | Pancreatic Adenocarcinoma | Oncology | Jun 2027 |
| NCT06159491 | Pacritinib | Phase 1 | Chronic Myelomonocytic Leukemia | Oncology | Jul 2027 |
| NCT05531786 | Pacritinib | Phase 1 | Graft vs Host Disease | Immunology | Jul 2027 |
| NCT04148430 | Anakinra | Phase 2 | B Cell ALL | Oncology | Oct 2027 |
| NCT04282187 | Pacritinib | Phase 2 | Acute Myeloid Leukemia | Oncology | Nov 2027 |
| NCT04858256 | Pacritinib | Phase 2 | T-Cell Neoplasm | Oncology | Nov 2027 |
| NCT07394153 | Pacritinib | Phase 2 | Myelofibrosis,MF | Oncology | Dec 2027 |
| NCT05611710 | Anakinra | Phase 2 | Dengue | Infectious disease | Dec 2027 |
| NCT06675123 | Pacritinib | Phase 1 | Recurrent Mantle Cell Lymphoma | Oncology | Mar 2028 |
| NCT05926505 | Anakinra | Phase 2 | Post-Acute COVID-19 Syndrome | Infectious disease | Mar 2028 |
| NCT05267821 | Anakinra | Phase 2 | Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS) | Infectious disease | May 2028 |
| NCT06381661 | Anakinra | Phase 2 | Sepsis | Infectious disease | Aug 2028 |
| NCT06986174 | Pacritinib | Phase 2 | Waldenström Macroglobulinemia | Oncology | Oct 2028 |
| NCT03165734 | Pacritinib | Phase 3 | Primary Myelofibrosis | Hematology | Oct 2028 |
| NCT06940830 | Efanesoctocog alfa | Phase 4 | Hemophilia A | Hematology | Dec 2028 |
| NCT07148947 | Pacritinib | Phase 2 | Accelerated Phase Myeloproliferative Neoplasm | Oncology | Dec 2028 |
| NCT07226713 | Pacritinib | Phase 2 | Prostate Cancer | Oncology | Mar 2029 |
| NCT07503834 | Anakinra | Phase 1 | Pancreatic Transplant | Immunology | Apr 2029 |
| NCT06218628 | Pacritinib | Phase 1 | Primary Myelofibrosis | Oncology | Aug 2029 |
| NCT06303193 | Pacritinib | Phase 1 | Myelodysplastic Syndromes | Hematology | Jan 2030 |
| NCT07447817 | Pacritinib | Phase 2 | Myelofibrosis | Hematology | May 2030 |
| NCT05013450 | Anakinra | Phase 1 | Metastatic Non-small Cell Lung Cancer | Oncology | Sep 2030 |
| NCT07746895 | Pegcetacoplan | Phase 4 | C3 Glomerulopathy (C3G) | Genitourinary | Dec 2031 |
| NCT06052618 | Pacritinib | Phase 2 | KSHV Inflammatory Cytokine Syndrome (KICS) | Oncology | Jan 2033 |
Theradex Pfizer Roche Bristol-Myers Squibb AbbVie GSK Daiichi Sankyo Sinocelltech Octapharma ASC Therapeutics
Octapharma Jiangsu vcare pharmaceutical technology Bausch Health Americas Brainfarma Industria Química e Farmacêutica S/A Servier Affaires Médicales
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.